Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. (IMDX): 6 pipeline candidates · 1 upcoming catalyst · ~11 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
11.3 months
D/E -4.78 · 7% dilution
Lead: Approved
6 candidates
1 upcoming, next in ~348d
14 buys · 0 sells (180d)
A transparent, data-derived signal for Insight Molecular Diagnostics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$171.8M
Cash
$28.2M
Quarterly Burn
$7.6M
Runway
11.3 mo
Revenue
$32K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| [18f]pi-2620 | Phase 3 |
| determacni | Preclinical |
| determaio | Preclinical |
| graftassurecore | Approved |
| graftassuredx | Phase 3 |
| graftassureiq | Preclinical |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
39
Total value held
$53.9M
| Holder | Shares | Value |
|---|---|---|
| broadwood capital inc | 11,931,839 | $39.1M |
| vanguard capital management llc | 1,074,322 | $3.5M |
| pura vida investments, llc | 947,134 | $3.1M |
| alyeska investment group, l.p. | 840,777 | $2.8M |
| heights capital management, inc | 392,545 | $1.3M |
| geode capital management, llc | 262,053 | $860K |
| blackrock, inc. | 135,345 | $444K |
| vanguard fiduciary trust co | 132,591 | $435K |
| family office research llc | 127,266 | $417K |
| millennium management llc | 103,470 | $339K |
Showing top 10 of 39 institutional holders of Insight Molecular Diagnostics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Insight Molecular Diagnostics Inc.'s pipeline?
Insight Molecular Diagnostics Inc. (IMDX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Insight Molecular Diagnostics Inc.'s lead drug candidate?
Insight Molecular Diagnostics Inc.'s most advanced tracked candidate is [18f]pi-2620 (Phase 3) for Alzheimer Disease.
What is Insight Molecular Diagnostics Inc.'s next catalyst?
Insight Molecular Diagnostics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safet" — expected June 1, 2027.
What is Insight Molecular Diagnostics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Insight Molecular Diagnostics Inc. has approximately 11.3 months of cash runway.
What is Insight Molecular Diagnostics Inc.'s market capitalization?
Insight Molecular Diagnostics Inc.'s market capitalization is approximately $171.8M.
Get the full picture on Insight Molecular Diagnostics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.